Get the Stockscreener App
14.06
3.43%
-0.50
Pre-market:
15.00
0.94
+6.69%
Amarin Corp Adr stock is traded at $14.06, with a volume of 38,353.
It is down -3.43% in the last 24 hours and down -6.14% over the past month.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
See More
Previous Close:
$14.56
Open:
$14.6
24h Volume:
38,353
Relative Volume:
0.53
Market Cap:
$294.83M
Revenue:
$217.21M
Net Income/Loss:
$-33.72M
P/E Ratio:
-8.6769
EPS:
-1.6204
Net Cash Flow:
$25.63M
1W Performance:
-6.39%
1M Performance:
-6.14%
6M Performance:
-15.86%
1Y Performance:
+32.89%
1-Day Range:
$14.01
$14.75
1-Week Range:
$14.01
$15.29
52-Week Range:
$10.34
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Name
Amarin Corp Adr
Sector
Industry
Phone
353 1 6699 020
Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
14.06 | 305.31M | 217.21M | -33.72M | 25.63M | -1.6204 |
LLY
Lilly Eli Co
|
988.09 | 896.13B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.92 | 545.74B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
209.41 | 371.72B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
183.92 | 281.60B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.15 | 282.55B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Oct-25-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| May-06-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-04-22 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-12-21 | Downgrade | Goldman | Neutral → Sell |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| May-05-20 | Initiated | Northland Capital | Outperform |
| Mar-31-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-31-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Mar-13-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-02-20 | Initiated | Cowen | Outperform |
| Feb-18-20 | Upgrade | Citigroup | Neutral → Buy |
| Jan-06-20 | Initiated | JP Morgan | Neutral |
| Dec-16-19 | Downgrade | Stifel | Buy → Hold |
| Nov-20-19 | Initiated | Oppenheimer | Underperform |
| Nov-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Nov-15-19 | Reiterated | SVB Leerink | Outperform |
| Oct-31-19 | Initiated | Aegis Capital | Buy |
| Oct-15-19 | Initiated | Goldman | Neutral |
| Aug-14-19 | Initiated | SVB Leerink | Outperform |
| Jul-09-19 | Reiterated | Jefferies | Buy |
| Jun-17-19 | Initiated | ROTH Capital | Buy |
| Mar-22-19 | Initiated | Stifel | Buy |
View All
Amarin Corp Adr Stock (AMRN) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Amarin shareholders reject key proposals at annual meeting, limit equity grants - Investing.com
AMRN Technical Analysis | Trend, Signals & Chart Patterns | AMARIN CORP PLC -ADR (NASDAQ:AMRN) - ChartMill
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales - TradingView
Amarin (AMRN) Loss Trend Of 24.2% Annually Tests Turnaround Narratives Heading Into Q1 - Sahm
Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs - ChartMill
Amarin Corp PLC (FRA:EH3) Stock Price, Trades & News - GuruFocus
Amarin Corporation Plc Sponsored ADR Trade Ideas — FWB:EH3 - TradingView
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks - The Motley Fool
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz
Amarin Corporation Plc Sponsored ADR Trade Ideas — SWB:EH3 - TradingView
Amarin (NASDAQ: AMRN) details VASCEPA reach, Recordati deal and $70M savings - Stock Titan
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss - Finviz
Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 - ChartMill
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Finviz
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - Finviz
China Universal Asset Management Co. Ltd. Sells 76,302 Shares of Amarin Corporation PLC $AMRN - Defense World
Net current asset value per share of Amarin Corporation Plc Sponsored ADR – MUN:EH3 - TradingView — Track All Markets
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth - Sahm
Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight - Law360
Tops & Flops Stocks - sharewise.com
Amarin (AMRN) Unprofitable as Losses Worsen, Profit Growth Forecasts Test Bullish Turnaround Hopes - Sahm
Leerink Partners raises Amarin stock price target to $12 on strong Q3 - Investing.com
FDA updates fenofibrate labels to reflect lack of cardiovascular benefit - Investing.com
Amarin stock rises after ESC Congress data on VASCEPA mechanism - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect - Finviz
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Finviz
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - Finviz
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin stock jumps after $25 million licensing deal with Recordati - Investing.com
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Finviz
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease - Finviz
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Finviz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines - Finviz
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - Finviz
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies - Finviz
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
Global X Aging Population ETF Holdings - Quiver Quantitative
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
Amarin Corp Adr Stock (AMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):